Navigation Links
Bunge Limited to Expand Sugar and Bioenergy Business in Brazil
Date:12/24/2009

ction chain. The company supplies fertilizer to farmers; originates, transports and processes oilseeds, grains and other agricultural commodities; produces food products for commercial customers and consumers; and supplies raw materials and services to the biofuels industry.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains both historical and forward-looking statements. All statements, other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are not based on historical facts, but rather reflect our current expectations and projections about our future results, performance, prospects and opportunities. We have tried to identify these forward-looking statements by using words including "may," "will," "should," "could," "expect," "anticipate," "believe," "plan," "intend," "estimate," "continue" and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. The following important factors, among others, could affect our business and financial performance: industry conditions, including fluctuations in supply, demand and prices for agricultural commodities and other raw materials and products used in our business, fluctuations in energy and freight costs and competitive developments in our industries; the effects of weather conditions and the outbreak of crop and animal disease on our business; global and regional agricultural, economic, financial and commodities market, political, social and health conditions; the outcome of pending regulatory and l
'/>"/>

SOURCE Bunge Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bunge Reports Fourth Quarter Net Income of $245 Million
2. Bunge Limited Schedules Third Quarter 2008 Earnings Release and Conference Call
3. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
4. Sunrise Biotech Holding Limited Application For Admission to PLUS
5. Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
6. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
7. Limited transparency in federal nanotech research may hamper development
8. Application for Listing of Shire Limited Ordinary Shares
9. Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced
10. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
11. EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test Opportunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... and Companies" to their offering. ... based on technologies and applications. The report starts ... for estimation of markets. Technologies include array comparative ...
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:9/2/2015)... 02, 2015 ... announced the addition of Jain PharmaBiotech,s new ... Companies" to their offering. ... besides fluorescence in situ hybridization (FISH), comparative ... cytogenetics includes application of nanobiotechnology, microarrays, real-time ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... of botanical and plant-derived compounds. BCC Research reveals in its new report ... because this market defines the category and generates the most market demand. ...
Breaking Biology Technology:Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... (Nasdaq: AMGN ) today announced that results ... trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX ... metastatic colorectal cancer (mCRC), respectively, were published online in ... "Both studies demonstrated that Vectibix administered with chemotherapy ...
... 4 Reportlinker.com announces that a new market ... Global Soft Tissue Allografts Industry ... report analyzes the worldwide markets for Soft Tissue ... Cartilage Allografts, Meniscus Allografts, and Tendon Allografts. The ...
... Inc., the U.S.-based group company of Shionogi & ... Drug Administration approval of the non-stimulant medication KAPVAY™ ... for the treatment of Attention Deficit Hyperactivity Disorder ... KAPVAY™ is the only formulation of clonidine hydrochloride ...
Cached Biology Technology:Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11Reportlinker Adds Global Soft Tissue Allografts Industry 2Reportlinker Adds Global Soft Tissue Allografts Industry 3Reportlinker Adds Global Soft Tissue Allografts Industry 4Reportlinker Adds Global Soft Tissue Allografts Industry 5Reportlinker Adds Global Soft Tissue Allografts Industry 6Reportlinker Adds Global Soft Tissue Allografts Industry 7Reportlinker Adds Global Soft Tissue Allografts Industry 8Reportlinker Adds Global Soft Tissue Allografts Industry 9Reportlinker Adds Global Soft Tissue Allografts Industry 10Reportlinker Adds Global Soft Tissue Allografts Industry 11Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 2Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 3Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 4Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 5Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 6
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... concern for enterprises, banks, government organizations, telecommunication and hospitals ... assets. Keys, identity badges, and numeric keypads are used ... the structure of palm and fingers of an individual, ... Hand geometry scanners with infrared light and reflectors can ...
(Date:9/2/2015)... , Sept. 2, 2015 Security ... concern for enterprises, banks, government organizations, telecommunications, hospitals, ... numeric keypads were previously being used to prevent ... of two-factor authentication, wherein individuals could gain access ... different components, such as hardware devices and numeric ...
(Date:9/2/2015)... 2, 2015 Biometric ... in a system which uses identical human characteristic ... vein, DNA and finger print. Increasing number of ... such system which provides high level of security. ... and tokens are vulnerable to attacks. Furthermore, Biometric ...
Breaking Biology News(10 mins):Global Hand Geometry Biometrics Market 2015-2019 2Global Hand Geometry Biometrics Market 2015-2019 3Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4
... fish populations leaving them in danger of total collapse, ... measures in place to control fish stocks may not ... research, which is published in today's Nature, involved compiling ... non-exploited fish off the California coast. The research team ...
... Researchers from the University of Pennsylvania School of Veterinary Medicine ... of fish and mammals in the form of a primitive ... system. Their studies link the evolution of the adaptive ... fight infection, to the more primitive innate immunity in fish, ...
... Institut Pasteur has recently shown that the tuberculosis bacillus ... cells. This formidable pathogen is protected against even the ... may remain dormant for years. This discovery, published in ... fighting tuberculosis. Attempts to eradicate the bacillus entirely from ...
Cached Biology News:Commercial fishing causes dangerous fluctuations in fish populations 2'Killer' B cells demonstrate evolutionary link between fish and mammal immune systems 2'Killer' B cells demonstrate evolutionary link between fish and mammal immune systems 3Tuberculosis: The bacillus takes refuge in adipose cells 2
... ActivePro In Vitro Translation ... E.coli lysate, synthesizes higher ... well as proteins with ... competing kits. This results ...
... off the clot fasted non-Swiss Albino mice of mixed ... N-02: Citrate N-04: Heparin ... Oxalate N-10: EDTA (Na) N-03: ... N-09: K3EDTA N-11: Heparin (K) ...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
Biology Products: